Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)
Status:
Unknown status
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Patients with extensive-stage small cell lung cancer receive six cycles of
chemotherapy(etoposide plus platinum) as first-line treatment,who achieve Complete
Response(CR)/Partial Response(PR) will accept small doses of etoposide as maintenance
treatment. The objective of this study is to evaluate the progression free survival,overall
survival,objective response rate,disease control rate and safety of etoposide as maintenance
therapy. Based on previous studies on maintenance therapy in small cell lung cancer,the
hypothesis of this study is maintenance therapy using etoposide may improve progression free
survival,overall survival for selected patients. The investigators will use the peripheral
blood to assess circulating tumor cell and cell-free DNA,which may help us to screen a
subgroup of patients with better response to etoposide maintenance therapy.